Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective lowered by equities researchers at Piper Sandler from $43.00 to $28.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler‘s price objective indicates a potential upside of 15.65% from the stock’s current price.

Other research analysts also recently issued reports about the company. Oppenheimer initiated coverage on Collegium Pharmaceutical in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price target on the stock. Weiss Ratings cut Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Needham & Company LLC dropped their price objective on Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday. Leerink Partners initiated coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 target price on shares of Collegium Pharmaceutical in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $24.21 on Friday. The company has a market cap of $788.28 million, a PE ratio of 24.21, a P/E/G ratio of 0.75 and a beta of 0.75. The firm’s 50 day moving average price is $22.99 and its 200-day moving average price is $32.79. The company has a debt-to-equity ratio of 3.65, a quick ratio of 0.84 and a current ratio of 1.13. Collegium Pharmaceutical has a 52-week low of $21.43 and a 52-week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.10. The company had revenue of $216.34 million during the quarter, compared to the consensus estimate of $216.03 million. Collegium Pharmaceutical had a net margin of 4.68% and a return on equity of 85.14%. Collegium Pharmaceutical’s revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.25 earnings per share. Sell-side analysts forecast that Collegium Pharmaceutical will post 6.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors have recently bought and sold shares of the company. Ritholtz Wealth Management increased its stake in Collegium Pharmaceutical by 150.7% during the 3rd quarter. Ritholtz Wealth Management now owns 20,305 shares of the specialty pharmaceutical company’s stock valued at $443,000 after purchasing an additional 12,205 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in shares of Collegium Pharmaceutical by 10.0% in the third quarter. Illinois Municipal Retirement Fund now owns 17,696 shares of the specialty pharmaceutical company’s stock worth $386,000 after buying an additional 1,607 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth $36,000. Profund Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 621.1% during the third quarter. Profund Advisors LLC now owns 65,710 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after buying an additional 56,597 shares during the period. Finally, Vise Technologies Inc. lifted its stake in shares of Collegium Pharmaceutical by 154.3% during the third quarter. Vise Technologies Inc. now owns 14,844 shares of the specialty pharmaceutical company’s stock worth $324,000 after buying an additional 9,006 shares during the period.

Key Headlines Impacting Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.